An illustration of oncolytic virus and an anti-PD-1 antibody working together to defeat cancer cells. An international study led by neurosurgeons at the University Health Network in Toronto reveals a novel therapy for glioblastoma that combines an oncolytic virus injection into the tumor with intravenous immunotherapy. The Phase 1/2 clinical trial demonstrates the therapy’s safety, effectiveness, and evidence of prolonged survival in select patients.
Investigative work by the authors also revealed a new genetic signature within tumor samples that has the potential to predict which patients with glioblastoma are most likely to respond to treatment. “Oncolytic viruses can overcome this limitation by creating a more favorable tumor microenvironment, which then helps to boost anti-tumor immune responses.”
“We’re very encouraged by these results,” says Dr. Farshad Nassiri, first author of the study and a senior neurosurgery resident at the University of Toronto. “Over half of our patients achieved a clinical benefit — stable disease or better — and we saw some remarkable responses with tumors shrinking, and some even disappearing completely. Three patients remain alive at 45, 48, and 60 months after starting the clinical trial.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: dailyherald - 🏆 317. / 59 Read more »
Source: mercnews - 🏆 88. / 68 Read more »
Source: KSLcom - 🏆 549. / 51 Read more »